Clinical Trial Update: Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

A pharmacodynamic/pharmacokinetic study of AQW051 in schizophrenia completed its Phase 1/2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AQW051

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Schizophrenia | Phase 1, Phase 2 | Status: COMPLETED